Pricing Log in Create free account

Curis, Inc. (CRIS) vs XTL Biopharmaceuticals Ltd. (XTLB)

Curis, Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. XTL Biopharmaceuticals Ltd. is the larger, with a market value of $7.3M against $5.7M — 1.3× the size. XTL Biopharmaceuticals Ltd. grew revenue faster over the last twelve months: −12.7% against −13.4%. Across the 12 metrics below, XTL Biopharmaceuticals Ltd. leads on 7 and Curis, Inc. on 5.

Valuation

Metric CRIS XTLB Biotechnology median
P/E n/m n/m 10.26
P/S 0.20 1.19 9.18
P/B 0.40 n/m 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.29 n/m 0.65
EV/Sales (0.27) 1.10 8.98
Earnings yield (1,634.48%) (28.44%) (34.89%)
Free cash flow yield (1,668.41%) (158.67%) (24.52%)

Profitability

Metric CRIS XTLB Biotechnology median
Gross margin 99.52% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 455.35% 0.00% (50.12%)
Return on assets (87.76%) 0.00% (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRIS XTLB Biotechnology median
Revenue growth (TTM) (13.43%) (12.71%) 6.26%
EPS growth (last fiscal year) 91.57% (409.84%) 29.88%
Revenue growth, 5-year CAGR (2.71%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRIS XTLB Biotechnology median
Debt to equity 0.00 (1.83) 0.00
Current ratio 0.49 0.70 4.89
Net debt to EBITDA 0.91 (0.11) 1.01

Dividend

Metric CRIS XTLB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRIS XTLB Biotechnology median
Market cap 5.67m 7.25m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack